Dispelling Doubts: Review Affirms Safety, Efficacy of Biosimilar Insulins

The Top 5 Center for Biosimilars Articles for the Week of January 8

January 12th 2024

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of January 8, 2024.

Eye on Pharma: Fresh Biosimilar Lawsuits; FDA to Review Ustekinumab, Denosumab Biosimilars

January 11th 2024

By Skylar Jeremias

As Regeneron gears up for a legal battle with biosimilar competitors for its reference aflibercept, CareFirst files a lawsuit against Johnson & Johnson for restricting biosimilar ustekinumab competition; Celltrion and Accord BioPharma file with the FDA to approve their respective biosimilar candidates.

EMA Approves First Ustekinumab Biosimilar, Uzpruvo

January 10th 2024

By Skylar Jeremias

The European Medicines Agency (EMA) has granted marketing authorization to the first ustekinumab biosimilar, STADA Arzneimittel and Alvotech’s Uzpruvo.

IQVIA Report Flags Challenges With Biosimilar Access, Savings Throughout Europe

January 10th 2024

By Skylar Jeremias

IQVIA’s report on the impact biosimilar competition has had on Europe’s health care space identified ongoing challenges with biosimilar access and generating savings, calling for more policies focusing on fostering a sustainable market for years to come.

Examining Attitudes in German, Swiss Pharmacists on Biosimilar Dispensing Pre- and Post Pandemic

January 9th 2024

By Cameron Santoro

A recent study found that the COVID-19 pandemic had little impact on the knowledge and attitudes of German and Swiss pharmacists regarding biologics and biosimilars between 2020 and 2022.

BioRationality: An Analysis of the Future of Biosimilars Through the Eyes of History

January 8th 2024

By Sarfaraz K. Niazi, PhD

Sarafraz K. Niazi, PhD, previews the new year and his hopes for the end of clinical efficacy testing for biosimilar approvals using examples from history of other scientific concepts that took time to gain traction.

Quiz: The Basics of Biosimilars

January 8th 2024

By The Center for Biosimilars Staff

Intro to Biosimilars is now in session! Test yourself on how well you know these biosimilar basics.

Dr Prerakkumar Parikh Reacts to FDA Approvals for First Neurology, Tocilizumab Biosimilars

January 7th 2024

By Brooke McCormick

Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.

CVS to Remove Humira From Some Reimbursement Lists in Favor of Biosimilar Options

January 6th 2024

Starting April 1, 2024, Hyrimoz and an unbranded version of Humira manufactured by Sandoz will be covered across all CVS formularies.

The Top 5 Biosimilar Articles for the Week of January 1

January 5th 2024

By Cameron Santoro

Here are the top 5 biosimilar articles for the week of January 1, 2024.